ALNY vs. COR: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALNY and COR, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
With ALNY at 38.15 billion USD and COR at 56.47 billion USD, their market capitalizations sit in the same ballpark.
COR carries a higher beta at 0.60, indicating it’s more sensitive to market moves, while ALNY remains steadier at 0.17.
| Symbol | ALNY | COR |
|---|---|---|
| Company Name | Alnylam Pharmaceuticals, Inc. | Cencora, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Distribution |
| CEO | Dr. Yvonne L. Greenstreet M.B.A., M.D. | Dr. Robert P. Mauch Ph.D., PharmD |
| Price | 292.58 USD | 291.36 USD |
| Market Cap | 38.15 billion USD | 56.47 billion USD |
| Beta | 0.17 | 0.60 |
| Exchange | NASDAQ | NYSE |
| IPO Date | June 1, 2004 | April 4, 1995 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALNY and COR over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALNY and COR based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ALNY posts a negative P/E of -140.68, reflecting last year’s net loss, while COR at 33.35 signals healthy earnings.
- ALNY posts a negative forward PEG of -38.16, hinting at anticipated earnings decline, whereas COR at 3.28 has projections for stable or growing earnings.
- ALNY has a negative Price-to-Free Cash Flow ratio of -506.05, signaling it consumed more cash than it produced over the last year—an important liquidity warning. In contrast, COR (P/FCF 15.80) indicates positive free cash flow generation.
| Symbol | ALNY | COR |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -140.68 | 33.35 |
| Forward PEG Ratio (TTM) | -38.16 | 3.28 |
| Price-to-Sales Ratio (P/S, TTM) | 16.25 | 0.18 |
| Price-to-Book Ratio (P/B, TTM) | 328.68 | 55.75 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -506.05 | 15.80 |
| EV-to-EBITDA (TTM) | -251.73 | 16.96 |
| EV-to-Sales (TTM) | 16.37 | 0.20 |
| EV-to-Free Cash Flow (TTM) | -509.80 | 17.44 |
Dividend Comparison
ALNY offers a 0% dividend yield, suggesting it may be reinvesting available cash back into the business for future growth, while COR provides a 0.74% dividend yield, giving investors a steady income stream.
| Symbol | ALNY | COR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.74% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALNY and COR, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- COR’s current ratio of 0.87 indicates its assets may not cover near-term debts, whereas ALNY at 3.04 maintains healthy liquidity.
- COR posts a quick ratio of 0.52, indicating limited coverage of short-term debts from its most liquid assets—while ALNY at 2.98 enjoys stronger liquidity resilience.
- ALNY and COR both have debt-to-equity ratios above 3 (11.28 and 7.76), reflecting aggressive use of debt that can amplify gains but also increase vulnerability to rising rates.
- With negative EBIT (-0.79), ALNY cannot cover its interest payments. COR, with an interest coverage of 9.41, meets its interest obligations.
| Symbol | ALNY | COR |
|---|---|---|
| Current Ratio (TTM) | 3.04 | 0.87 |
| Quick Ratio (TTM) | 2.98 | 0.52 |
| Debt-to-Equity Ratio (TTM) | 11.28 | 7.76 |
| Debt-to-Assets Ratio (TTM) | 0.31 | 0.11 |
| Interest Coverage Ratio (TTM) | -0.79 | 9.41 |